STOCK TITAN

[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Corcept Therapeutics (CORT) director reports option exercise and sale. On 10/10/2025, the reporting person exercised 2,200 stock options at $14.08 per share and sold 2,200 shares at $87.54, both reported as direct holdings. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.

Following these transactions, common stock directly held was 0 shares. The filer reports 1,100 derivative securities (stock options) remaining directly owned, which are fully exercisable and carry an expiration date of 08/20/2028.

Corcept Therapeutics (CORT) direttore riferisce esercizio di opzioni e vendita. Il 10/10/2025, la persona che ha fornito la relazione ha esercitato 2.200 opzioni azionarie a 14,08 USD per azione e ha venduto 2.200 azioni a 87,54 USD, entrambe riportate come partecipazioni dirette. La vendita è stata effettuata in conformità a un piano di trading Rule 10b5-1 adottato il 1 agosto 2024.

A seguito di queste operazioni, le azioni ordinarie detenute direttamente risultano 0 azioni. Il dichiarante segnala 1.100 strumenti derivati (opzioni azionarie) ancora detenuti direttamente, totalmente esercitabili e con scadenza il 20/08/2028.

Corcept Therapeutics (CORT) director reports option exercise and sale. El 10/10/2025, la persona que presentó el informe ejerció 2,200 opciones sobre acciones a 14,08 USD por acción y vendió 2,200 acciones a 87,54 USD, ambas reportadas como participaciones directas. La venta se realizó conforme a un plan de trading Rule 10b5-1 adoptado el 1 de agosto de 2024.

Después de estas operaciones, las acciones comunes directamente poseídas eran 0. El declarante reporta 1,100 valores derivados (opciones sobre acciones) que siguen siendo propiedad directa, plenamente exercitables y con una fecha de vencimiento del 20/08/2028.

Corcept Therapeutics (CORT) 이사 옵션 행사 및 매도 보고. 2025년 10월 10일, 보고자는 주당 14.08달러에 2,200주 옵션을 행사하고 주당 87.54달러에 2,200주를 매도했으며, 둘 다 직접 보유로 보고되었습니다. 매도는 2024년 8월 1일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다.

이 거래 후 직접 보유 공통 주식은 0주로 남아 있습니다. 신고자는 여전히 직접 소유하고 완전히 행사 가능하며 만료일이 2028년 8월 20일인 1,100개의 파생 증권(주식 옵션)이 남아 있다고 보고합니다.

Corcept Therapeutics (CORT) administrateur signale l’exercice d’options et une vente. Le 10/10/2025, la personne déclarant a exercé 2 200 options sur actions à 14,08 USD par action et a vendu 2 200 actions à 87,54 USD, les deux opérant en tant que détentions directes. La vente a été réalisée conformément à un plan de trading Rule 10b5-1 adopté le 1er août 2024.

Suite à ces transactions, les actions ordinaires détenues directement s’élèvent à 0 titre. Le déclarant indique 1 100 valeurs dérivées (options sur actions) encore détenues directement, entièrement exerçables et ayant une échéance au 20/08/2028.

Corcept Therapeutics (CORT) Direktor meldet Optionsausübung und Verkauf. Am 10.10.2025 hat die meldende Person 2.200 Aktienoptionsscheine zu 14,08 USD pro Aktie ausgeübt und 2.200 Aktien zu 87,54 USD verkauft, beide als direkte Beteiligungen gemeldet. Der Verkauf erfolgte im Rahmen eines Rule 10b5-1-Handelsplans, der am 1. August 2024 eingeführt wurde.

Nach diesen Transaktionen betrug der direkt gehaltene Stammaktienbestand 0. Der Melder meldet 1.100 derivative Wertpapiere (Aktienoptionen), die weiterhin direkt gehalten werden, voll ausübbar sind und ein Ablaufdatum am 20.08.2028 haben.

مُدير CorCEPT Therapeutics (CORT) يُبلغ عن ممارسة خيار وبيع. في 10/10/2025، قام الشخص المُبلغ بممارسة 2,200 خيار أسهم عند 14.08 دولار أمريكي للسهم وببيع 2,200 سهم بسعر 87.54 دولار، وكلاهما مُبلغ عنه كملكيات مباشرة. تم البيع وفقاً لخطة تداول Rule 10b5-1 تم اعتمادها في 1 أغسطس 2024.

بعد هذه المعاملات، كانت قيمة الأسهم العادية المملوكة مباشرة 0 سهم. يُبلغ المُفَتِح عن وجود 1,100 أداة مشتقة (خيارات أسهم) متبقية مملوكة مباشرة، قابلة للممارسة بالكامل وتاريخ انتهاء صلاحيتها 20/08/2028.

Corcept Therapeutics (CORT) 董事报告了期权行使及出售。 在 2025/10/10,报告人以每股 14.08 美元的价格行使了 2,200 份股票期权,并以 87.54 美元的价格出售了 2,200 股股票,均以直接持有方式报告。此次出售是根据 2024 年 8 月 1 日通过的 Rule 10b5-1 交易计划进行的。

在这些交易之后,直接直接持有的普通股为 0 股。申报人报告仍直接拥有 1,100 份衍生证券(股票期权),这些期权完全可行使,到期日为 2028/08/20。

Positive
  • None.
Negative
  • None.

Corcept Therapeutics (CORT) direttore riferisce esercizio di opzioni e vendita. Il 10/10/2025, la persona che ha fornito la relazione ha esercitato 2.200 opzioni azionarie a 14,08 USD per azione e ha venduto 2.200 azioni a 87,54 USD, entrambe riportate come partecipazioni dirette. La vendita è stata effettuata in conformità a un piano di trading Rule 10b5-1 adottato il 1 agosto 2024.

A seguito di queste operazioni, le azioni ordinarie detenute direttamente risultano 0 azioni. Il dichiarante segnala 1.100 strumenti derivati (opzioni azionarie) ancora detenuti direttamente, totalmente esercitabili e con scadenza il 20/08/2028.

Corcept Therapeutics (CORT) director reports option exercise and sale. El 10/10/2025, la persona que presentó el informe ejerció 2,200 opciones sobre acciones a 14,08 USD por acción y vendió 2,200 acciones a 87,54 USD, ambas reportadas como participaciones directas. La venta se realizó conforme a un plan de trading Rule 10b5-1 adoptado el 1 de agosto de 2024.

Después de estas operaciones, las acciones comunes directamente poseídas eran 0. El declarante reporta 1,100 valores derivados (opciones sobre acciones) que siguen siendo propiedad directa, plenamente exercitables y con una fecha de vencimiento del 20/08/2028.

Corcept Therapeutics (CORT) 이사 옵션 행사 및 매도 보고. 2025년 10월 10일, 보고자는 주당 14.08달러에 2,200주 옵션을 행사하고 주당 87.54달러에 2,200주를 매도했으며, 둘 다 직접 보유로 보고되었습니다. 매도는 2024년 8월 1일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다.

이 거래 후 직접 보유 공통 주식은 0주로 남아 있습니다. 신고자는 여전히 직접 소유하고 완전히 행사 가능하며 만료일이 2028년 8월 20일인 1,100개의 파생 증권(주식 옵션)이 남아 있다고 보고합니다.

Corcept Therapeutics (CORT) administrateur signale l’exercice d’options et une vente. Le 10/10/2025, la personne déclarant a exercé 2 200 options sur actions à 14,08 USD par action et a vendu 2 200 actions à 87,54 USD, les deux opérant en tant que détentions directes. La vente a été réalisée conformément à un plan de trading Rule 10b5-1 adopté le 1er août 2024.

Suite à ces transactions, les actions ordinaires détenues directement s’élèvent à 0 titre. Le déclarant indique 1 100 valeurs dérivées (options sur actions) encore détenues directement, entièrement exerçables et ayant une échéance au 20/08/2028.

Corcept Therapeutics (CORT) Direktor meldet Optionsausübung und Verkauf. Am 10.10.2025 hat die meldende Person 2.200 Aktienoptionsscheine zu 14,08 USD pro Aktie ausgeübt und 2.200 Aktien zu 87,54 USD verkauft, beide als direkte Beteiligungen gemeldet. Der Verkauf erfolgte im Rahmen eines Rule 10b5-1-Handelsplans, der am 1. August 2024 eingeführt wurde.

Nach diesen Transaktionen betrug der direkt gehaltene Stammaktienbestand 0. Der Melder meldet 1.100 derivative Wertpapiere (Aktienoptionen), die weiterhin direkt gehalten werden, voll ausübbar sind und ein Ablaufdatum am 20.08.2028 haben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Swisher Daniel N JR

(Last) (First) (Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/10/2025 M 2,200 A $14.08 2,200 D
Common Stock 10/10/2025 S(1) 2,200 D $87.54 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $14.08 10/10/2025 M 2,200 (2) 08/20/2028 Common Stock 2,200 $0 1,100 D
Explanation of Responses:
1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 1, 2024 in effect at the time of this transaction.
2. Fully exercisable.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Daniel N. Swisher, Jr. 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CORT report on Form 4?

A director exercised 2,200 stock options at $14.08 and sold 2,200 shares at $87.54 on 10/10/2025.

Was the CORT insider sale under a 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1 plan adopted on August 1, 2024.

How many CORT shares did the insider hold after the transactions?

Common stock directly held was 0 shares following the reported transactions.

How many CORT options does the insider still hold?

The insider reports 1,100 stock options remaining directly owned.

What is the expiration date of the remaining CORT options?

The reported stock options carry an expiration date of 08/20/2028 and are fully exercisable.

What were the transaction codes on the CORT Form 4?

Code M for the option exercise and code S for the sale.
Corcept Therapeutics Inc

NASDAQ:CORT

CORT Rankings

CORT Latest News

CORT Latest SEC Filings

CORT Stock Data

8.09B
93.13M
11.55%
76.02%
10.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY